These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9121357)

  • 1. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
    Nilvebrant L; Hallén B; Larsson G
    Life Sci; 1997; 60(13-14):1129-36. PubMed ID: 9121357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
    Gillberg PG; Sundquist S; Nilvebrant L
    Eur J Pharmacol; 1998 May; 349(2-3):285-92. PubMed ID: 9671109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
    Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.
    Nilvebrant L
    Pharmacol Toxicol; 2002 May; 90(5):260-7. PubMed ID: 12076307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine.
    Hills CJ; Winter SA; Balfour JA
    Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.
    Nilvebrant L; Gillberg PG; Sparf B
    Pharmacol Toxicol; 1997 Oct; 81(4):169-72. PubMed ID: 9353847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D; Jarvis B
    Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological effects of tolterodine on human isolated urinary bladder.
    Yono M; Yoshida M; Wada Y; Kikukawa H; Takahashi W; Inadome A; Seshita H; Ueda S
    Eur J Pharmacol; 1999 Mar; 368(2-3):223-30. PubMed ID: 10193658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolterodine: an overview.
    Wefer J; Truss MC; Jonas U
    World J Urol; 2001 Nov; 19(5):312-8. PubMed ID: 11760779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity.
    Stahl MM; Ekström B; Sparf B; Mattiasson A; Andersson KE
    Neurourol Urodyn; 1995; 14(6):647-55. PubMed ID: 8750383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity.
    Guay DR
    Pharmacotherapy; 1999 Mar; 19(3):267-80. PubMed ID: 10221366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers.
    Chapple CR; Nilvebrant L
    Drugs R D; 2002; 3(2):75-81. PubMed ID: 12001821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
    Kobayashi S; Ikeda K; Miyata K
    Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle.
    Yono M; Yoshida M; Takahashi W; Inadome A; Ueda S
    BJU Int; 2000 Oct; 86(6):719-25. PubMed ID: 11069384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia.
    Van Kerrebroeck PE; Amarenco G; Thüroff JW; Madersbacher HG; Lock MT; Messelink EJ; Soler JM
    Neurourol Urodyn; 1998; 17(5):499-512. PubMed ID: 9776013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
    Larsson G; Hallén B; Nilvebrant L
    Urology; 1999 May; 53(5):990-8. PubMed ID: 10223495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
    Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
    Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.